Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Five-Year Outcomes of Lenadogene Nolparvovec Gene Therapy in Leber Hereditary Optic Neuropathy.

JAMA ophthalmology - 1 Feb 2025

Yu-Wai-Man Patrick, Newman Nancy J, Biousse Valérie, Carelli Valerio, Moster Mark L, Vignal-Clermont Catherine, Klopstock Thomas, Sadun Alfredo A, Sergott Robert C, Hage Rabih, Degli Esposti Simona, La Morgia Chiara, Priglinger Claudia, Karanja Rustum, Taiel Magali, Sahel José-Alain

Abstract excerpt

Importance: Limited studies have assessed the long-term benefit/risk of gene therapy for Leber hereditary optic neuropathy (LHON). Objective: To determine the safety and efficacy of lenadogene nolparvovec in patients with LHON due to the MT-ND4 gene variant for up to 5 years after administration. Design, Setting, and Participants: The RESCUE and REVERSE Long-Term Follow-up Study (RESTORE), conducted from 2018 to...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Dependovirus
Share to DNA, Mitochondrial

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Follow-Up Studies

Share to Genetic Therapy

Share to Genetic Vectors

Share to NADH Dehydrogenase

Share to Optic Atrophy, Hereditary, Leber

Share to Visual Acuity

Source

Open in PubMed Open full text

Identifiers

PMID: 39699886
DOI: 10.1001/jamaophthalmol.2024.5375
PMCID: PMC11843360

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 17 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Five-Year Outcomes of Lenadogene Nolparvovec Gene Therapy in Leber Hereditary Optic Neuropathy.PMID 39699886Read ↗

Long-Term Follow-Up After Unilateral Intravitreal Gene Therapy for Leber Hereditary Optic Neuropathy: The RESTORE Study.Semantic proximity Read ↗

Efficacy and Safety of Intravitreal Gene Therapy for Leber Hereditary Optic Neuropathy Treated within 6 Months of Disease Onset.Semantic proximity Read ↗

Safety of Intravitreal Gene Therapy for Treatment of Subjects with Leber Hereditary Optic Neuropathy due to Mutations in the Mitochondrial ND4 Gene: The REVEAL Study.Semantic proximity Read ↗

Long-term outcomes of gene therapy for the treatment of Leber's hereditary optic neuropathy.Semantic proximity Read ↗

Safety of rAAV2/2-ND4 Gene Therapy for Leber Hereditary Optic NeuropathySemantic proximity Read ↗

Leber Hereditary Optic Neuropathy Gene Therapy Clinical Trial RecruitmentSemantic proximity Read ↗

Gene Therapy for Leber Hereditary Optic Neuropathy: Initial Results.Semantic proximity Read ↗

The Progress of Gene Therapy for Leber's Optic Hereditary Neuropathy.Semantic proximity Read ↗

Leber Hereditary Optic Neuropathy Gene Therapy: Adverse Events and Visual Acuity Results of All Patient GroupsSemantic proximity Read ↗

Randomized trial of bilateral gene therapy injection for m.11778G>A MT-ND4 Leber optic neuropathy.Semantic proximity Read ↗

Biodistribution of intravitreal lenadogene nolparvovec gene therapy in nonhuman primatesSemantic proximity Read ↗

Leber's hereditary optic neuropathy: course of disease in consideration of idebenone treatment and type of mutation.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.